Erdanib 4 mg (Erdafitinib) – 60 Tablets

Description

Product Features:

What is Erdanib 4 mg (Erdafitinib)?

Erdanib 4 mg (Erdafitinib) an oral tyrosine kinase inhibitor (TKI). It selectively inhibits the function of fibroblast growth factor receptors (FGFRs), which are responsible for cellular proliferation, survival and expansion. Some cancers are driven or progressed by mutations or other alterations in their FGFR genes. Erdanib blocks these receptors and inhibits the signaling pathways that promote cancer growth, providing a targeted treatment approach.

Indications: What Conditions Does Erdanib Treat?

Erdanib 4 mg has been primarily approved for locally advanced or metastatic urothelial carcinoma (UC), a malignant tumor of the urinary system, including bladder cancer. It is indicated for use in patients whose tumors have FGFR2 or FGFR3 genetic alterations vulnerable to this form of treatment. These modifications are detected by means of genetic testing, so that the treatment is directed at patients most likely to profit from it.

How Does Erdanib Work? Mechanism of Action

Erdanib is a selective inhibitor of FGFR1, FGFR2, FGFR3, and FGFR4. These receptors, when mutated, can promote aberrant cell growth and survival in tumor cells. Erdanib acts by blocking these receptors.

1. Arrests Tumor Growth: Stops cancer cells from multiplying;
2. Triggers Apoptosis: Wills cancer cells to die by way of apoptosis.
3. Angiogenesis Inhibitor: Limits new blood vessel growth needed for tumor subintake.

By targeting specific cancer cells to minimize damage to healthy cells and, therefore, reduce the unpleasant side effects of traditional chemo.

Dosage and Administration

• First dose: 8 mg (2 tablets of 4 mg, which are the only available); once daily by mouth
• Thereafter, the dose may be increased as described above, to 9 mg once daily, based on patient response and tolerability.
• Erdanib should be hydrating and can be taken with or without food.
• FGFR inhibitors are associated with an elevation of serum phosphate levels, requiring regular monitoring of these values.

Benefits of Erdanib 4 mg

1. Erdanib is for precision medicine, with targeted action in patients with certain genetic alterations.
2. Better Outcomes: There are published responses in patients with FGFR-altered urothelial carcinoma in clinical studies, including previously progressed patients on other treatments.
3. Oral Administration: In contrast to intravenous chemotherapy, Erdanib is an oral medication, allowing for greater convenience and flexibility in administration for the patient.

Potential Side Effects

Erdanib is well tolerated, but some possible adverse reactions include:

• Hyperphosphatemia (increased phosphate in blood)
• Fatigue
• Dry mouth
• Nausea and vomiting
• Diarrhea
• Eye defects

Most of these side effects can be managed with regular monitoring and dose adjustment.

Precautions and Warnings

• You will need regular eye exams to check for possible vision-related side effects.
• Patients are advised to avoid strong CYP2C9 and CYP3A4 inhibitors or inducers because these will affect the metabolism of Erdanib.
• Women of childbearing potential should use highly effective contraception, as fetal harm can occur with Erdafitinib.

To prevent complications, kidney and liver function monitoring is required.

The Future of Erdanib and FGFR Inhibitors

Erdanib is an important advance for the treatment of FGFR-driven malignancies.” It is also being researched in other cancers like cholangiocarcinoma (bile duct cancer) and breast cancer that have high prevalence of FGFR alterations. With precision medicine on the rise, drugs such as Erdanib provide potential for novel therapies for cancer that will be more effective and will be less toxic to patients.

Drug Interactions

• CYP3A4 inducers can reduce the efficacy of Erdanib.
• Inhibitors of CYP2C9 may increase the concentration of the drug and risk of toxicity.
• However, because phosphate-binding agents decrease phosphate, they may impair drug efficacy.

Storage and Handling

Store at 20°C to 25°C (68°F to 77°F). Protect from moisture and light. Keep out of reach of children.

Supplied Partner

All the intravenous drugs are delivered with guaranteed lowest price from Emergency Drug. They are also partnered with trustworthy manufacturers further maintaining a high standard for their medicines. With a customer-first approach they are your Trusted Partner in all things Pharmaceuticals.

Conclusion

The treatment of FGFR-altered urothelial carcinoma has dramatically changed with the introduction of a novel targeted therapy: erdanib 4 mg (Erdafitinib) FibroGen, San Francisco, CA) [4]. By targeting the genetic underpinnings of cancer, it provides a targeted and effective form of treatment that has fewer side effects than conventional treatments. As further study is expanded, the range of usages for Erdanib and comparable medications is likely to extend, as they carry with them promise for cancer patients globally.

Visit for more related medicine

Disclaimer: This information is provided solely for educational reasons and should not be considered medical advice. Always consult with your doctor or healthcare professional before taking any drug.